Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.45 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15800111 | 1.00 | CA1 (0.48) | CA1CA2FDPSALDH1A1CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL28118106 | 0.98 | CA1 (0.47) | CA1CA2FDPSALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL29047451 | 0.98 | CA1 (0.47) | CA1CA2FDPSALDH1A1CYP3A4 | |
| SCHEMBL5138404 | 0.93 | CA1 (0.57) | CA1FDPSACE2ZDHHC7 | |
| SCHEMBL16298859 | 0.93 | CA1 (0.57) | CA1FDPSACE2ZDHHC7 | |
| SCHEMBL11869095 | 0.91 | CA1 (0.55) | CA1FDPSACE2ZDHHC7 | |
| SCHEMBL8963949 | 0.91 | CA1 (0.55) | CA1FDPSACE2ZDHHC7 | |
| SCHEMBL3677429 | 0.91 | CA1 (0.55) | CA1FDPSACE2ZDHHC7 | |
| SCHEMBL3673850 | 0.91 | CA1 (0.55) | CA1FDPSACE2ZDHHC7 | |
| SCHEMBL14169844 | 0.91 | CA1 (0.55) | CA1FDPSACE2ZDHHC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117396477-A | Pyridyl-substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司 | 2024-01-12 | — | — | CN | claimed |
| CN-106676084-B | A kind of lipase mutant, encoding gene and its application from thermophilic ankle section bacterium | 浙江工业大学 | 2019-11-29 | — | — | CN | claimed |
| CN-104293744-B | Talaromyces thermophilus derived lipase mutant and application thereof | 浙江工业大学 | 2017-04-12 | — | — | CN | claimed |
| CN-1034501-C | (Bemzhydryloxyethylpiperidyl) aliphatic acid derivatives and their use in the treatment of allergies and asthma | SANKYO CO (JP) | 1997-04-09 | — | — | CN | claimed |
| CN-1058773-A | (diphenyl-methyl oxyethyl group piperidyl) aliphatic acid derivative and the purposes in treatment allergy and asthma thereof | SANKYO CO (JP) | 1992-02-19 | — | — | CN | claimed |
| CN-118401524-A | Material for organic electroluminescent device | 默克专利有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-111801833-B | Nonaqueous electrolyte and energy device using same | 三菱化学株式会社 | 2024-07-16 | — | — | CN | disclosed |
| CN-111788733-B | Nonaqueous electrolyte and power storage device using same | 三菱化学株式会社 | 2024-02-02 | — | — | CN | disclosed |
| CN-117396477-A | Pyridyl-substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司 | 2024-01-12 | — | — | CN | disclosed |
| US-11858948-B2 | Hydrogenation of carbonyls with tetradentate PNNP ligand ruthenium complexes | FIRMENICH SA (CH) | 2024-01-02 | — | — | US | disclosed |
| US-11858948-B2 | Hydrogenation of carbonyls with tetradentate PNNP ligand ruthenium complexes | FIRMENICH SA (CH) | 2024-01-02 | — | — | US | disclosed |
| CN-117120429-A | KHK inhibitor | 吉利德科学公司 | 2023-11-24 | — | — | CN | disclosed |
| US-4096342-A | 8β,12α,15β-PGE2 compounds | THE UPJOHN COMPANY (US) | 1978-06-20 | — | — | US | disclosed |
| US-4095036-A | 8β,12α,15β-PGF2 β Compounds | THE UPJOHN COMPANY (US) | 1978-06-13 | — | — | US | disclosed |
| US-4084063-A | PROSTAGLANDINS; ANTIULCER AGENTS, ANTICOAGULANTS, OXYTOCICS, DECONGESTANTS | THE UPJOHN COMPANY (US) | 1978-04-11 | — | — | US | disclosed |
| US-3987085-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
| US-3969396-A | 8β, 11β, 12α-PGE2 compounds | THE UPJOHN COMPANY (US) | 1976-07-13 | — | — | US | disclosed |
| US-3954833-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-05-04 | — | — | US | disclosed |
| US-3933889-A | 4,5-Cis-didehydro-PGF1.sub.α analogs | THE UPJOHN COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
| US-3931279-A | 5-Oxa prostaglandin F2.sub.α analogs | THE UPJOHN COMPANY (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858948-B2 | Hydrogenation of carbonyls with tetradentate PNNP ligand ruthenium complexes | ADH1C, ADH1A, ADH5 | CA1 613/4885CA2 2957/4885FDPS 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.